KR101036058B1 - 폐질환 증상의 치료 및 예방 - Google Patents

폐질환 증상의 치료 및 예방 Download PDF

Info

Publication number
KR101036058B1
KR101036058B1 KR1020047017208A KR20047017208A KR101036058B1 KR 101036058 B1 KR101036058 B1 KR 101036058B1 KR 1020047017208 A KR1020047017208 A KR 1020047017208A KR 20047017208 A KR20047017208 A KR 20047017208A KR 101036058 B1 KR101036058 B1 KR 101036058B1
Authority
KR
South Korea
Prior art keywords
delete delete
leu
gly
pro
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020047017208A
Other languages
English (en)
Korean (ko)
Other versions
KR20050019073A (ko
Inventor
챨스 지. 코크레인
Original Assignee
더 스크립스 리서치 인스티튜트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 스크립스 리서치 인스티튜트 filed Critical 더 스크립스 리서치 인스티튜트
Publication of KR20050019073A publication Critical patent/KR20050019073A/ko
Application granted granted Critical
Publication of KR101036058B1 publication Critical patent/KR101036058B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/785—Alveolar surfactant peptides; Pulmonary surfactant peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020047017208A 2002-04-25 2003-04-25 폐질환 증상의 치료 및 예방 Expired - Fee Related KR101036058B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37596802P 2002-04-25 2002-04-25
US60/375,968 2002-04-25

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020117002442A Division KR20110017465A (ko) 2002-04-25 2003-04-25 폐질환 증상의 치료 및 예방

Publications (2)

Publication Number Publication Date
KR20050019073A KR20050019073A (ko) 2005-02-28
KR101036058B1 true KR101036058B1 (ko) 2011-05-19

Family

ID=29270737

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020047017208A Expired - Fee Related KR101036058B1 (ko) 2002-04-25 2003-04-25 폐질환 증상의 치료 및 예방
KR1020117002442A Ceased KR20110017465A (ko) 2002-04-25 2003-04-25 폐질환 증상의 치료 및 예방

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117002442A Ceased KR20110017465A (ko) 2002-04-25 2003-04-25 폐질환 증상의 치료 및 예방

Country Status (13)

Country Link
US (2) US7863241B2 (enExample)
EP (1) EP1558273B1 (enExample)
JP (2) JP4651946B2 (enExample)
KR (2) KR101036058B1 (enExample)
CN (1) CN1838964A (enExample)
AT (1) ATE520411T1 (enExample)
AU (1) AU2003223718B2 (enExample)
CA (1) CA2483102C (enExample)
IL (2) IL164795A0 (enExample)
MX (1) MXPA04010560A (enExample)
NZ (1) NZ536796A (enExample)
WO (1) WO2003090682A2 (enExample)
ZA (1) ZA200408573B (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010560A (es) 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.
AU2004296206A1 (en) * 2003-12-04 2005-06-23 The Scripps Research Institute Treatment and preventions of asthma
WO2005073246A2 (en) * 2004-01-20 2005-08-11 Discovery Laboratories, Inc. Method for preparing kl4 lung surfactant
JP4160615B2 (ja) * 2004-03-11 2008-10-01 レドックス・バイオサイエンス株式会社 プロテアーゼ阻害剤
US7553810B2 (en) 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
US7608579B2 (en) 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281800A1 (en) 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue
EP1781182B1 (en) 2004-07-08 2019-11-13 PneumRx, Inc. Pleural effusion treatment device
BRPI0515163A (pt) * 2004-09-10 2008-07-08 Pharmaorigin Aps métodos para tratar hemoptise ou sangramento traqueal, brÈnquico ou alveolar local
US8337815B2 (en) * 2004-12-23 2012-12-25 Discovery Laboratories, Inc. Pulmonary surfactant formulations
EP1830810A4 (en) * 2004-12-30 2011-02-02 Dobeel Co Ltd SPRAY-DRYED COMPOSITION WITH PROTEINS OF THE COLLECTIN FAMILY OR VARIATIONS THEREOF AND METHOD OF PREPARATION THEREOF
GB0510463D0 (en) * 2005-05-23 2005-06-29 Britania Pharmaceuticals Ltd Improvements in or relating to organic materials
BRPI0613137A2 (pt) * 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
WO2007005672A2 (en) * 2005-06-30 2007-01-11 The Scripps Research Institute Treatment and prevention of respiratory diseases and conditions
AU2008232677B2 (en) * 2007-03-29 2013-09-19 National Jewish Health Surfactant lipids, compositions thereof, and uses thereof
EP1997502A1 (en) * 2007-06-01 2008-12-03 CHIESI FARMACEUTICI S.p.A. Reconstituted surfactants having improved properties
CN101754747A (zh) * 2007-06-05 2010-06-23 Paka肺部医药公司 用于向肺脏递送药物的方法以及组合物
WO2009073843A1 (en) * 2007-12-06 2009-06-11 Cytotech Labs, Llc Inhalable compositions having enhanced bioavailability
GB0724772D0 (en) * 2007-12-19 2008-01-30 Ucl Business Plc Carrier
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
US8785390B2 (en) 2009-01-30 2014-07-22 Alphabeta Ab Methods for treatment of Alzheimer's disease
US8434479B2 (en) 2009-02-27 2013-05-07 Covidien Lp Flow rate compensation for transient thermal response of hot-wire anemometers
WO2011016534A1 (ja) * 2009-08-06 2011-02-10 一般財団法人化学及血清療法研究所 咳嗽抑制効果を持つ血漿タンパク質
EP2308489B1 (en) * 2009-10-05 2014-01-01 Nutri-Fit GmbH & Co. KG Compositions for use in treating or preventing metabolic stress-induced lung injury and methods for increasing physical capacity of mammalian livestock
ES2679819T3 (es) 2009-11-03 2018-08-31 Grifols Therapeutics Inc. Composición, método y kit para inhibidor de alfa-1 proteinasa
CA2781120C (en) 2009-11-24 2015-01-27 Jianxin Guo Lyophilization methods, compositions, and kits
GB201003559D0 (en) * 2010-03-03 2010-04-21 Proteo Biotech Ag Novel use of elafin
ES2664793T3 (es) 2010-03-12 2018-04-23 Berg Llc Formulaciones intravenosas de coenzima Q10 (CoQ10) y métodos de uso de las mismas
JP5893614B2 (ja) 2010-06-24 2016-03-23 アルファベータ・エービーＡｌｐｈａＢｅｔａ ＡＢ アルツハイマー病および家族性認知症の治療のための化合物および方法
CN101897720B (zh) * 2010-07-27 2015-09-09 北京华禧联合科技发展有限公司 一种治疗呼吸道疾病的药物组合物
US8623832B2 (en) * 2010-11-04 2014-01-07 The Board Of Regents Of The University Of Oklahoma Peptide compositions that bind TLR-4
US20130184202A1 (en) * 2011-02-08 2013-07-18 Changjiang Guo Peptide Inhibitors and Methods of Use Thereof
WO2012138284A1 (en) 2011-04-05 2012-10-11 Alphabeta Ab Amyloidosis target useful in methods of treatment and for screening of compounds
US9642888B2 (en) 2011-04-12 2017-05-09 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
US9890200B2 (en) 2011-04-12 2018-02-13 Moerae Matrix, Inc. Compositions and methods for preventing or treating diseases, conditions, or processes characterized by aberrant fibroblast proliferation and extracellular matrix deposition
MX351781B (es) 2011-06-17 2017-10-30 Berg Llc Composiciones farmaceuticas inhalables.
US9089657B2 (en) 2011-10-31 2015-07-28 Covidien Lp Methods and systems for gating user initiated increases in oxygen concentration during ventilation
WO2013188016A2 (en) * 2012-05-04 2013-12-19 Discovery Laboratories, Inc. Surfactant therapy for exposure to ionizing radiation
JP2016532456A (ja) 2013-09-18 2016-10-20 ジェームス・クック・ユニバーシティー 改変型抗炎症性タンパク質及び使用方法
EP3046575A4 (en) * 2013-09-18 2017-04-05 James Cook University Anti-inflammatory proteins and methods of use
WO2015061412A1 (en) * 2013-10-22 2015-04-30 The Scripps Research Institute Methods and compositions for promoting bronchioli dilatation
US20180221462A1 (en) * 2014-08-26 2018-08-09 Proteo Biotech Ag Use of elafin for disorders associated with elastase independent increase in troponin
EP3300474A4 (en) 2015-04-27 2019-01-30 OmniActive Health Technologies Limited BETTUBO TOXIN COMPOSITIONS, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
WO2021207514A1 (en) * 2020-04-08 2021-10-14 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treating and preventing lung disease
EP3512539A4 (en) * 2016-09-13 2020-07-29 Prothera Biologics, Inc. METHODS FOR TREATING LUNG DISEASE USING INTER-ALPHA INHIBITOR PROTEINS
CN118161614A (zh) * 2017-03-31 2024-06-11 艾娜呼吸私人有限公司 用tlr2激动剂治疗呼吸道感染
EP3727353A4 (en) * 2017-12-21 2021-10-13 Civitas Therapeutics, Inc. SURFACTANT FORMULATIONS FOR INHALATION
EP3781123A1 (en) * 2018-04-17 2021-02-24 Lamellar Biomedical Limited Antifibrotic composition
WO2020037146A1 (en) * 2018-08-17 2020-02-20 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of acute lung injury
US12221471B2 (en) 2018-10-19 2025-02-11 Ohio State Innovation Foundation Nanocarriers for lung inflammation therapy
BR112021007692A2 (pt) * 2018-10-23 2021-08-10 George Edward Hoag composição e método para tratar os pulmões
JP7689492B2 (ja) * 2018-10-30 2025-06-06 ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド 嚢胞性線維症を治療するためのアミノ酸組成物及び方法
JP2022542519A (ja) * 2019-08-01 2022-10-04 サープラス テクノロジー エルエルシー 酸化耐性セルピン
KR102276935B1 (ko) * 2020-02-06 2021-07-12 한양대학교 산학협력단 신규한 비올라크산틴 고생산 클로렐라 불가리스 균주 및 이로부터 비올라크산틴을 생산하는 방법
CN115245559A (zh) * 2021-04-25 2022-10-28 上海萨美细胞技术有限公司 一种用于治疗肺损伤的药物
WO2024097169A1 (en) * 2022-11-01 2024-05-10 National Jewish Health Treatment of coronavirus infections with antimicrobial phospholipid compositions
CN116421704A (zh) * 2023-02-20 2023-07-14 成都佩德生物医药有限公司 多肽pd-dp-005在制备治疗肺部疾病药物中的应用及其药物
CN120000688B (zh) * 2025-04-16 2025-08-05 山东杰凯生物科技有限公司 基于干细胞外囊泡的雾化吸入组合物及其制备方法、应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013619A1 (en) * 2002-11-22 2006-01-19 Kabushiki Kaisha Toshiba Image forming apparatus with stopper for preventing rotation of a developing unit

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57144224A (en) * 1981-03-02 1982-09-06 Mochida Pharmaceut Co Ltd Remedy for respiratory dieseases
US4916117A (en) * 1986-12-24 1990-04-10 John Lezdey Treatment of inflammation using alpha 1-antichymotrypsin
US5164369A (en) * 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) * 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5707634A (en) 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
NO177716C (no) * 1989-06-09 1995-11-08 Zeneca Ltd Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
JPH04506809A (ja) * 1989-07-11 1992-11-26 ジェネンテク，インコーポレイテッド 界面活性剤組成物および方法
US5993805A (en) 1991-04-10 1999-11-30 Quadrant Healthcare (Uk) Limited Spray-dried microparticles and their use as therapeutic vehicles
US5272252A (en) * 1991-11-04 1993-12-21 Merrell Dow Pharmaceuticals Inc. Synthetic lung surfactant having antioxidant properties
DE69313647T2 (de) * 1992-07-31 1998-03-12 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Synthetische peptide als lungensurfactants mit kovalent gebundenen antioxidantien
US5734014A (en) * 1992-08-11 1998-03-31 Tsumura & Co. Elafin derivative
AU5171293A (en) 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
US5301644A (en) 1993-06-16 1994-04-12 Kohler Co. Fuel shut-off mechanism for internal combustion engines
US5961970A (en) 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JP3721538B2 (ja) * 1994-06-02 2005-11-30 メレル ファーマスーティカルズ インコーポレイテッド エラスターゼのパーフルオロアルキルケトン阻害剤およびそれらを製造する方法
GB9413202D0 (en) 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
US5878912A (en) 1995-12-26 1999-03-09 Stein; Myron Duct disinfecting method and apparatus
US5874029A (en) 1996-10-09 1999-02-23 The University Of Kansas Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compressed antisolvent
US5833891A (en) 1996-10-09 1998-11-10 The University Of Kansas Methods for a particle precipitation and coating using near-critical and supercritical antisolvents
US5780440A (en) * 1996-06-17 1998-07-14 Protease Sciences Inc. Treatment of pulmonary disease with protease inhibitors
US6077543A (en) 1996-12-31 2000-06-20 Inhale Therapeutic Systems Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US6051257A (en) 1997-02-24 2000-04-18 Superior Micropowders, Llc Powder batch of pharmaceutically-active particles and methods for making same
JPH11147832A (ja) * 1997-11-18 1999-06-02 Noevir Co Ltd 好中球エラスターゼ阻害剤
JP3796340B2 (ja) * 1997-11-18 2006-07-12 株式会社ノエビア セリンプロテアーゼ阻害剤
US6284282B1 (en) 1998-04-29 2001-09-04 Genentech, Inc. Method of spray freeze drying proteins for pharmaceutical administration
US5883084A (en) * 1998-06-08 1999-03-16 Clarion Pharmaceuticals Inc. Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine
US6223455B1 (en) 1999-05-03 2001-05-01 Acusphere, Inc. Spray drying apparatus and methods of use
US7053176B1 (en) 1999-09-16 2006-05-30 Altana Pharma Ag Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
IL150485A0 (en) * 1999-12-28 2002-12-01 Novartis Ag Method of achieving persistent transgene expression
EP1251868A1 (en) * 2000-01-06 2002-10-30 Eli Lilly & Company Combination therapy for the treatment of inflammatory and respiratory diseases
MXPA04010560A (es) 2002-04-25 2005-08-15 Scripps Research Inst Tratamiento y prevencion de condiciones pulmonares.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060013619A1 (en) * 2002-11-22 2006-01-19 Kabushiki Kaisha Toshiba Image forming apparatus with stopper for preventing rotation of a developing unit

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Am. J. Crit. Care Med. Vol.159, p917-p923 (1999)*

Also Published As

Publication number Publication date
JP4651946B2 (ja) 2011-03-16
US20050070477A1 (en) 2005-03-31
AU2003223718A1 (en) 2003-11-10
CN1838964A (zh) 2006-09-27
IL164795A (en) 2011-02-28
EP1558273B1 (en) 2011-08-17
JP2005529885A (ja) 2005-10-06
AU2003223718B2 (en) 2007-08-16
ATE520411T1 (de) 2011-09-15
KR20110017465A (ko) 2011-02-21
ZA200408573B (en) 2006-03-29
KR20050019073A (ko) 2005-02-28
EP1558273A2 (en) 2005-08-03
US20120189602A1 (en) 2012-07-26
IL164795A0 (en) 2005-12-18
WO2003090682A2 (en) 2003-11-06
NZ536796A (en) 2007-03-30
CA2483102A1 (en) 2003-11-06
AU2003223718C1 (en) 2003-11-10
JP2011001383A (ja) 2011-01-06
US7863241B2 (en) 2011-01-04
WO2003090682A3 (en) 2004-09-16
CA2483102C (en) 2013-06-18
EP1558273A4 (en) 2008-07-16
MXPA04010560A (es) 2005-08-15

Similar Documents

Publication Publication Date Title
KR101036058B1 (ko) 폐질환 증상의 치료 및 예방
JP2005529885A5 (enExample)
EP1833503B1 (en) Pulmonary surfactant formulations
JP2013177422A (ja) サーファクタント処置療法
US20070129297A1 (en) Treatment and prevention of asthma
WO2007005672A2 (en) Treatment and prevention of respiratory diseases and conditions
RU2496515C2 (ru) Введение в дыхательные пути активированного белка с при воспалительных состояниях, поражающих дыхательные пути
MXPA00003231A (en) Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions
HK1109078B (en) Surfactant treatment regimen for treating or preventing bronchopulmonary dysplasia
HK1109077B (en) Pulmonary surfactant formulations

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R15-X000 Change to inventor requested

St.27 status event code: A-3-3-R10-R15-oth-X000

R16-X000 Change to inventor recorded

St.27 status event code: A-3-3-R10-R16-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20140422

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20150416

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20160419

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170514

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170514